Dr. Carl June's CAR-T Cell Journey and the Cancer Treatment Revolution

Dr. Carl June's CAR-T Cell Journey and the Cancer Treatment Revolution

FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. It reprograms the body's own immune system to recognize and kill cancer cells. The therapy initially called CAR-T cell immunotherapy and now named Kymriah by Novartis, is approved to treat children and young adults with a recurrent form of the blood cancer called acute lymphoblastic leukemia (ALL). Dr. Carl June of University of Pennsylvania, is one of the pioneers of CAR-T cell research and leads the team responsible for the historic FDA approval. We are discussing Dr. Junes CAR-T cell journey to understand nuances of the new therapy. The discussion will also bring to focus the opportunity that these engineered immune cells present to cancer treatment and possible use in treatment of other cancers.


Talk Recorded on Nov. 15, 2017, 1 p.m.   EST 28

  • Anonymous User Nov. 15, 2017, 1:45 p.m.  US/Eastern

    If CarT fails say in 5 years, would the process be repeated?

  • Anonymous User Nov. 15, 2017, 1:43 p.m.  US/Eastern

    Is there an advisory board of researchers which will help guide a patient cancer support group to which immunotherapy platform is best matched with there particular tumor etiology? For example, CAR-T therapy vs ACT vs Crispr.

  • Anonymous User Nov. 15, 2017, 1:40 p.m.  US/Eastern

    Please tell me about the UPENN CAR-T clinical trial for follicular lymphoma (fNHL): * How many fNHL patients in the trial? * How many fNHL patients achieved a complete remission? * How many fNHL patients remain in complete remission? * How long has the complete remission lasted? William May

  • Anonymous User Nov. 15, 2017, 1:33 p.m.  US/Eastern

    Why are you letting one person dominate the Q&A? Please give other participants a chance to ask questions.

  • Anonymous User Nov. 15, 2017, 1:25 p.m.  US/Eastern

    Will girls treated with this therapy be able to reproduce?

  • Anonymous User Nov. 15, 2017, 1:23 p.m.  US/Eastern

    Wouldn't it be better if we didn't use chemotherapy but started these patients with CAR T-cells? instead of so late?

  • Anonymous User Nov. 15, 2017, 1:19 p.m.  US/Eastern

    What is the longest remission known so far from CarT?

  • Anonymous User Nov. 15, 2017, 1:18 p.m.  US/Eastern

    What is the best method to test to see if a patients immune system is recognizing or failing to recognize a tumor? Specifically, epithelioid hemangioendothelioma since we have not identified a protein or antigen yet.

  • Anonymous User Nov. 15, 2017, 1:16 p.m.  US/Eastern

    Do you think BCMA-targeting CARTs could bring cures for multiple myeloma? Would this maybe be used first eventually or only after PIs and IMiDs or dara? Thank you from the midwest...

  • Anonymous User Nov. 15, 2017, 1:02 p.m.  US/Eastern

    Will CAR-T cell therapy be considered for frontline treatment? Will CAR-T cell tx prove to be much more expensive than traditional protocols? Is there any consensus in the MM medical community that efforts should be strongly earmarked for CAR-T cell therapy? What has been the age range of trial participants? Sean M.

  • Anonymous User Nov. 15, 2017, 12:59 p.m.  US/Eastern

    Has Show started or are there some minutes to start?

  • priya menon Nov. 15, 2017, 12:54 p.m.  US/Eastern

    Please dial in on this number if you would like to ask a question: (718) 664-6574

  • Anonymous User Nov. 15, 2017, 12:33 p.m.  US/Eastern

    I lost my link to the meeting Is there any way you can resend thanks Philip Segal segalfamily@sympatico.ca

  • Anonymous User Nov. 15, 2017, 11:03 a.m.  US/Eastern

    In the UPENN CAR-T clinical trial of follicular lymphoma patients: How many people were in the trial? How many people achieved a complete remission? How many people are still in complete remission? What is the average length of the complete response? What is the longest duration of the complete response?

  • Anonymous User Nov. 14, 2017, 9:29 p.m.  US/Eastern

    Hello Dr June, I have followed your works for a couple of years with great excitement and anticipation! I am the Director of Patient Liaison Services for a Facebook Cancer Support Group for a very rare sarcoma called epithelioid hemangioendothelioma (EHE for short). This mysterious vascular tumor develops in the lining of vessels. We know EHE occurs as a result of a gene fusion with WWTR1-CAMTA1, this discovery was made by Dr Brian Rubin-Cleveland Clinic. Has CAR-T therapy been tried on sarcoma and if so, which form(s)? Currently EHE has no standard of care or cure. Our support group has 1270+ members eager to work with you! Go to our non-profit foundation-www.fightehe.org. Respectfully, Lisa De Young

  • Anonymous User Nov. 14, 2017, 3:32 p.m.  US/Eastern

    I have stage IV colon cancer is this something that can treat this.

  • Anonymous User Nov. 11, 2017, 5:28 p.m.  US/Eastern

    Would CAR-T Cell treatment be effective in Advanced Prostate cancer? Any upcoming trials?

  • Anonymous User Nov. 11, 2017, 5:23 p.m.  US/Eastern

    Due to time differences between the US and Australia, will it be possible to watch the session after the live event? Many thanks

    Show / Hide Replies

    Priya Menon Nov. 13, 2017, 1:02 a.m.  US/Eastern

    Reply: Hi! Yes, the talk will be archived and will be available on the same page to listen at leisure. Thanks!

  • Anonymous User Nov. 8, 2017, 6:31 a.m.  US/Eastern

    Is this treatment for older people only?

  • Nov. 8, 2017, 6:29 a.m.  US/Eastern

    is this treatment for younger people

  • Anonymous User Nov. 7, 2017, 5:59 p.m.  US/Eastern

    Is this treatment offered for 55 yrs and older? What are the differences between UPENNs CAR T therapy and other's like Juno etc . What should family's look at when comparing CAR T treatments? Thanks in advance for all the work you and your colleagues have done to find a cure!

  • Anonymous User Nov. 7, 2017, 10:24 a.m.  US/Eastern

    Hi - for Multiple Myeloma, it seems some people are pursuing BCMA with a CAR-T approach and others are going after it with bispecifics. Do you think one approach is better than another? Would CAR-Ts be more toxic? Many thanks...

  • Anonymous User Nov. 6, 2017, 11:44 p.m.  US/Eastern

    When would this treatment become available for AML?

  • Anonymous User Nov. 6, 2017, 2:42 p.m.  US/Eastern

    Firstly Dr Carl June, amazing work and congratulations to you and everyone involved, fantastic. Do you think 5T4 expressed on many solid tumours may be an interesting target perhaps combined with a PD-1? At the moment Novartis use Oxford Biomedica`s Lentivector delivery system. Do you think that this type of delivery will be used for the foreseeable future? Would it be possible to deliver virus to T-cells in the patient directly without the need for isolating, transforming and amplifying the cells ex-vivo?

  • Anonymous User Nov. 5, 2017, 2:48 p.m.  US/Eastern

    Hello Dr. June, What is the exclusion criteria for CAR-T cell therapies in the multiple myeloma patient population? Will CAR-T therapies preclude a myeloma patient from future treatments and/ or clinical trials should the CAR-T not be effective? Which antigen target is most promising and potentially curative in myeloma? Is it BCMA? Is it CD19? Aren't most myeloma cells CD19 negative? or perhaps a combination of both targets ? And finally, what are the differences in the various CAR-T cell therapy products in the myeloma patient clinical trials ? UPENN's vs Celgene, Juno, Poseida, etc. Thank you.

  • Anonymous User Nov. 4, 2017, 1:39 a.m.  US/Eastern

    Are there any special preparations a patient needs to get done prior to this therapy? Thanks.

  • Anonymous User Nov. 4, 2017, 1:37 a.m.  US/Eastern

    Would be great if Dr. June can talk about side effects of this treatment.

  • Anonymous User Nov. 1, 2017, 11:15 p.m.  US/Eastern

    Is there discussion or interest in testing for multiple myeloma patients?